Madrigal Pharmaceuticals, Inc. (MDGL) fair value analysis
Nasdaq · Updated 2026-09-07
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medicines for cardiovascular and metabolic diseases. The company operates in the United States and is headquartered in Conroe, Texas.
Valuation status
Awaiting full valuationMDGL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $482.00
- Sector
- Healthcare
- 12-month range
- $412.35–$593.87
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The lower-middle quarter of its range
What our data shows for MDGL
- Shares are trading in the middle of their 12-month price range of $412.35–$593.87.
- The 14-day relative strength index sits at a neutral 57.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MDGL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent MDGL news
TickrTrends' derived news-sentiment signal for MDGL is currently leaning positive, computed from recent coverage.
- Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Amid Elevated Price-to-Sales Valuation (gurufocus.com, 2026-09-02)
TickrTrends take: Madrigal Pharmaceuticals is experiencing significant capital expenditure growth within the Healthcare sector at a time when its price-to-sales valuation stands elevated relative to peers. TickrTrends is currently awaiting full valuation metrics on MDGL, which means investors focused on valuation should monitor whether the company's substantial CapEx investments translate into revenue growth that could justify its current pricing. The intersection of elevated valuations and heightened capital spending creates a critical inflection point where execution on revenue generation will be essential for valuation support. - Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference (manilatimes.net, 2026-09-02)
TickrTrends take: Madrigal Pharmaceuticals' participation in the 2026 Cantor Global Healthcare Conference provides an opportunity for investors to assess management commentary and pipeline updates that could inform the company's valuation as TickrTrends completes its analysis. The conference setting typically allows for detailed discussions on clinical progress, commercial strategy, and financial outlook, all of which are relevant inputs for establishing a comprehensive valuation in the Healthcare sector. Investors awaiting TickrTrends' full valuation should monitor any announcements regarding product development milestones or market positioning that emerge from the company's conference participation. - Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors (manilatimes.net, 2026-08-12)
TickrTrends take: Madrigal's appointment of John C. Reed, M.D., Ph.D., to its board adds scientific and medical expertise to the company's governance during a period when TickrTrends awaits sufficient data to complete a full valuation assessment. In the Healthcare sector, board composition and the caliber of medical leadership can influence investor confidence in a company's strategic direction and pipeline oversight. Valuation-focused readers should monitor whether this appointment correlates with any announcements regarding clinical progress, regulatory milestones, or strategic initiatives that could provide the data points needed to move from a valuation-pending status to a completed assessment.
What people are saying
Follow the MDGL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MDGL stock undervalued?
MDGL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is MDGL's TickrTrends verdict?
MDGL is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is MDGL overbought or oversold?
MDGL's 14-day RSI is in neutral territory - neither overbought nor oversold.